Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACETAZOLAMIDE vs INJECTAPAP
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Reversible inhibition of carbonic anhydrase, primarily in the proximal renal tubule, reducing hydrogen ion secretion and increasing bicarbonate, sodium, potassium, and water excretion. Also reduces aqueous humor formation via ocular carbonic anhydrase inhibition.
Acetaminophen is a centrally acting analgesic and antipyretic; its exact mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system and modulation of descending serotonergic pathways. It does not have significant anti-inflammatory activity.
Edema due to congestive heart failure (adjunctive therapy),Drug-induced edema,Centrencephalic epilepsies (petit mal, unlocalized seizures),Chronic simple (open-angle) glaucoma,Secondary glaucoma,Preoperative lowering of intraocular pressure in acute angle-closure glaucoma,Altitude sickness (prevention and treatment),Off-label: Idiopathic intracranial hypertension, metabolic alkalosis, sleep apnea, bipolar disorder, cystinuria, hypokalemic periodic paralysis
Management of mild to moderate pain,Reduction of fever
250-500 mg orally twice daily or 250 mg intravenously twice daily; for edema, 250-375 mg orally once daily; for altitude sickness, 250 mg orally every 8-12 hours.
1 g intravenous every 6 hours or 650 mg intravenous every 4 hours; maximum 4 g per day.
Terminal half-life approximately 10–15 hours; prolonged in renal impairment (up to 30+ hours).
2-3 hours in adults; prolonged to 4-6 hours in neonates and patients with hepatic impairment.
Primarily excreted unchanged in urine (70-100%). Minor metabolism via hydrolysis of acetyl group (possibly by plasma esterases) to acetazolamide, and glucuronide conjugation.
Primarily metabolized in the liver via conjugation (glucuronidation and sulfation) at therapeutic doses; a minor pathway via cytochrome P450 (CYP2E1, CYP1A2, and CYP3A4) produces a toxic metabolite (NAPQI) which is normally detoxified by glutathione.
Renal: ~90% unchanged drug via tubular secretion and glomerular filtration; minor biliary/fecal (<2%).
Renal: 2-5% unchanged; hepatic metabolism to glucuronide and sulfate conjugates, then renal excretion of metabolites. Biliary/fecal: minimal (<5%).
~70–90% bound primarily to carbonic anhydrase in erythrocytes and plasma proteins (albumin).
10-25% bound to albumin at therapeutic concentrations.
0.2–0.3 L/kg; concentrates in tissues with high carbonic anhydrase content (RBCs, kidneys, eyes).
0.8-1.0 L/kg; suggests distribution into total body water.
Oral: ~100% (well absorbed); IV: 100%.
IV: 100%; oral: 60-90% (first-pass metabolism); rectal: 30-50%.
Cr Cl 10-50 m L/min: administer every 12 hours; Cr Cl <10 m L/min: avoid use (ineffective).
For GFR 30-60 m L/min: no adjustment; for GFR <30 m L/min: extend interval to every 8 hours; maximum 3 g per day.
Child-Pugh class A: no adjustment; Child-Pugh class B-C: caution, reduce dose by 50% and monitor for encephalopathy.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%, maximum 2 g per day; Child-Pugh C: contraindicated.
Children: 5-10 mg/kg/dose orally or IV every 8-12 hours; maximum 500 mg/dose.
For weight ≥50 kg: 1 g every 6 hours; for weight 10-50 kg: 15 mg/kg every 6 hours; for weight <10 kg: 7.5 mg/kg every 6 hours; all intravenous.
Initiate at lowest effective dose (250 mg daily) due to increased risk of electrolyte disturbances and renal impairment.
No specific dose adjustment required; consider decreased hepatic function and concomitant medications; maximum 3 g per day for patients with risk factors for hepatotoxicity.
WARNING: Metabolically induced acidosis. Use with caution in patients with hepatic cirrhosis to avoid precipitation of hepatic encephalopathy. Not recommended for long-term use in patients with chronic noncongestive angle-closure glaucoma due to risk of increased intraocular pressure with lens displacement.
Acetaminophen has been associated with cases of acute liver failure, hepatotoxicity is primarily due to overdose. Risk is increased in patients with underlying liver disease, chronic alcohol use, and those taking multiple acetaminophen-containing products.
Sulfonamide hypersensitivity reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) - discontinue at first sign of rash,Metabolic acidosis - monitor electrolytes, use with caution in patients with respiratory acidosis or those at risk,Hepatic impairment - contraindicated in cirrhosis; may precipitate hepatic encephalopathy,Renal impairment (Cr Cl <10 m L/min) - ineffective and may cause metabolic acidosis,Hematologic reactions (agranulocytosis, aplastic anemia) - monitor CBC,Hypercalciuria and renal stone formation - ensure adequate hydration,Drowsiness, confusion, fatigue - impaired ability to drive/operate machinery,Use in pregnancy - potential risk; cross-sensitivity with sulfonamides
Risk of hepatotoxicity, especially with doses exceeding 4 g/day or in patients with liver impairment,Severe skin reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, and acute generalized exanthematous pustulosis,Hypersensitivity reactions,Use caution in patients with G6PD deficiency,Avoid use with other acetaminophen-containing products
Hypersensitivity to acetazolamide or any sulfonamide derivative,Severe hepatic cirrhosis or hepatic impairment,Severe renal impairment (Cr Cl <10 m L/min) or anuria,Hyponatremia or hypokalemia,Adrenocortical insufficiency (Addison's disease),Long-term use in chronic noncongestive angle-closure glaucoma,Metabolic acidosis
Hypersensitivity to acetaminophen or any component of the formulation
Avoid high doses of vitamin C or cranberry juice as they may acidify urine and decrease drug effectiveness. Maintain adequate hydration; no specific food restrictions.
No significant food interactions. However, concurrent ingestion of alcohol may increase risk of hepatotoxicity; avoid alcohol while on therapy.
First trimester: Avoid; associated with increased risk of congenital malformations (limb defects, hypospadias). Second and third trimesters: Use only if clearly needed; may cause fetal metabolic acidosis, electrolyte disturbances, and growth retardation.
FDA Category C. Acetaminophen crosses the placenta. No evidence of teratogenicity in humans with standard doses. First trimester: limited data suggest no increased risk of major malformations. Second and third trimesters: chronic high-dose use may be associated with increased risk of childhood asthma and attention-deficit/hyperactivity disorder (ADHD). Overdose poses risk of maternal and fetal hepatotoxicity.
Excreted into breast milk (M/P ratio approximately 0.25). Not recommended due to risk of sulfonamide-related adverse effects (e.g., kernicterus in jaundiced infants, hemolytic anemia in G6PD deficiency).
Acetaminophen is excreted into breast milk in low concentrations (M/P ratio approximately 0.91-1.42). Reported infant dose is less than 2% of maternal weight-adjusted dose. Considered compatible with breastfeeding. Use lowest effective dose for shortest duration.
No standard dose adjustment recommended; pharmacokinetics altered (increased Vd, decreased Cmax) but clinical significance uncertain. Monitor for metabolic acidosis and adjust if necessary.
No dose adjustment required for standard therapeutic use. Increased clearance in pregnancy may require shorter dosing intervals for pain control; consider maximum daily dose of 3 g/day instead of 4 g/day. Avoid prolonged use >48 hours without medical supervision.
Acetazolamide is a carbonic anhydrase inhibitor used for glaucoma, altitude sickness, and as a diuretic. Monitor serum electrolytes (especially potassium and bicarbonate) due to metabolic acidosis risk. Avoid in severe hepatic or renal impairment. Can cause paresthesias, especially in hands and feet. Use with caution in patients with sulfonamide allergy as cross-reactivity is possible but rare.
Acetaminophen injection is indicated for treatment of acute pain and fever. Use with caution in hepatic impairment. Avoid in patients with severe active liver disease. Monitor liver function tests with prolonged use. Do not exceed maximum daily dose (4 g/day in adults). Use the smallest effective dose for the shortest duration.
Take exactly as prescribed; do not stop suddenly.,May cause tingling or numbness in fingers, toes, or mouth; this is usually temporary.,Drink plenty of fluids unless otherwise directed; avoid excessive alcohol.,Report unusual fatigue, muscle cramps, or rapid breathing to your doctor.,Avoid prolonged sun exposure; use sunscreen as photosensitivity may occur.,If used for altitude sickness, start 1-2 days before ascent and continue during climb.
Do not take more than the recommended dose. Overdose can cause severe liver damage.,Inform your healthcare provider if you have liver disease or drink alcohol regularly.,Check other medications for acetaminophen to avoid double dosing.,Seek immediate medical attention if you experience signs of liver injury (e.g., yellowing skin/eyes, dark urine, upper stomach pain).,This medication is administered by intravenous infusion; do not attempt self-administration.
"Bosutinib, a potent CYP3A4 inhibitor, can significantly increase the serum concentration of acetazolamide, a carbonic anhydrase inhibitor, by reducing its hepatic metabolism. This elevation may potentiate acetazolamide's adverse effects, including metabolic acidosis, electrolyte imbalances (e.g., hypokalemia), and paresthesias, especially in patients with renal impairment. Clinicians should monitor for signs of acetazolamide toxicity when coadministered with bosutinib."
"Acetazolamide, a carbonic anhydrase inhibitor, can cause metabolic acidosis and decrease renal tubular secretion of metformin, potentially increasing metformin plasma concentrations. This combination may elevate the risk of lactic acidosis, a rare but serious adverse effect of metformin. Additionally, acetazolamide-induced hypokalemia can exacerbate metformin-associated hyperlactatemia."
"Acetazolamide, a carbonic anhydrase inhibitor, increases urinary pH and promotes bicarbonate excretion, leading to metabolic alkalosis. This systemic alkalinization enhances renal tubular reabsorption of lithium, paradoxically decreasing lithium clearance and increasing serum lithium concentrations. Clinically, this can precipitate lithium toxicity, manifesting as nausea, tremor, ataxia, or confusion, particularly in patients on stable lithium regimens."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACETAZOLAMIDE vs INJECTAPAP, answered by our medical review team.
ACETAZOLAMIDE is a Carbonic Anhydrase Inhibitor that works by Reversible inhibition of carbonic anhydrase, primarily in the proximal renal tubule, reducing hydrogen ion secretion and increasing bicarbonate, sodium, potassium, and water excretion. Also reduces aqueous humor formation via ocular carbonic anhydrase inhibition.. INJECTAPAP is a Non-Opioid Analgesic that works by Acetaminophen is a centrally acting analgesic and antipyretic; its exact mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system and modulation of descending serotonergic pathways. It does not have significant anti-inflammatory activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACETAZOLAMIDE and INJECTAPAP depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACETAZOLAMIDE is: 250-500 mg orally twice daily or 250 mg intravenously twice daily; for edema, 250-375 mg orally once daily; for altitude sickness, 250 mg orally every 8-12 hours.. The standard adult dose of INJECTAPAP is: 1 g intravenous every 6 hours or 650 mg intravenous every 4 hours; maximum 4 g per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACETAZOLAMIDE and INJECTAPAP in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACETAZOLAMIDE is classified as Category C. First trimester: Avoid; associated with increased risk of congenital malformations (limb defects, hypospadias). Second and third trimesters: Use only if clearly needed; may cause f. INJECTAPAP is classified as Category C. FDA Category C. Acetaminophen crosses the placenta. No evidence of teratogenicity in humans with standard doses. First trimester: limited data suggest no increased risk of major ma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.